Please assess the completion status of the following clinical trial:

Trial Title: Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old.~* Must carry a diagnosis of lichen planus as determined by biopsy~* Patients must have a score of 3 or greater on the physician global assessment (PGA).~* Patient must be considered appropriate for systemic therapy based upon fulfilling one of the following criteria:~  1. inability to maintain weight due to pain with eating, chewing, or swallowing;~ 2. dyspareunia or dysuria due to genital lesions;~ 3. itch/pain of sufficient severity that activities of daily living are significantly affected~* Must be off systemic lichen planus treatment for 4 weeks prior to starting etanercept~* If using topical corticosteroid to the affected areas, the dose and frequency must be unchanged for 2 weeks prior to beginning the study agent and during the course of the study.~* Must be off topical cyclosporine, tacrolimus, or pimecrolimus for 2 weeks prior to starting the study drug and for the entire duration of the study.~* Must be able and willing to give written informed consent and comply with the requirements of the study protocol and must authorize release and use of protected health information.~* Women of childbearing potential must have a negative pregnancy test at the time of entry into the study and must be practicing successful contraception for at least 3 months prior to the study.~* Subject or designee must have the ability to self-inject investigational product.~* Screening laboratory results are within the following parameters:~  * Hemoglobin \> 10 g/dL~ * White blood cells \> 3.5 x 10\^9/L~ * Neutrophils \> 1.5 x 10\^9/L~ * Platelets \> 100 x 10\^9/L~ * Lymphocytes \> 0.5 x 10\^9/L~ * Serum creatinine \< 1.5 mg/dL~ * Hepatitis C serology - nonreactive~ * AST and ALT \< 2X upper limit of normal (ULN)~Exclusion Criteria:~* Subject is currently enrolled in another investigational device or drug trial(s), or subject has received investigational agent(s) within 90 days of baseline visit.~* Known HIV-positive status, any other immuno-suppressive disease, or inability to practice safe sex during the length of the study~* Subject has been diagnosed with a malignancy within the past 5 years~* Subject has signs or symptoms of a lymphoproliferative disease.~* Other skin or mucosal disease that might interfere with lichen planus assessments.~* Lichen planus variants including hypertrophic, atrophic, follicular (including lichen planopilaris), and bullous cutaneous forms.~* Patients with lichen sclerosis et atrophicus (LS\&A)~* Clinical history and lesion distribution suspicious for a lichenoid drug eruption~* Severe co-morbidities~* History of tuberculosis (TB) or positive PPD at screening. Known history of active hepatitis B or C, or lupus, SLE, history of multiple sclerosis or prior episode of central nervous system demyelination, transverse myelitis, optic neuritis, epilepsy, psychiatric condition, or other chronic serious medical illnesses.~* Subject has a diagnosis of congestive heart failure (CHF) of any severity~* Use of a live vaccine 90 days prior to, or during this study.~* Previous exposure and/or known sensitivity to etanercept~* Concurrent use, or failure of, any TNF-inhibitor~* Previous exposure to alefacept or efalizumab within 6 weeks of administration of study drug~* Concurrent sulfasalazine therapy~* Prior or concurrent cyclophosphamide therapy~* Active severe infections, or prior infection requiring hospitalization or oral/intravenous antibiotics within 4 weeks before screening visit, or between the screening and baseline visits.~* Active inflammatory bowel disease or peptic ulcer disease~* Drug or alcohol abuse within 12 months of screening visit.~* History of non-compliance with other therapies~* Pregnant or lactating~* Documented presence of any of the following:~  * Proteinuria \> 1+ by dipstick screening~ * 24 Hour protein excretion \> 0.5 g~ * Symptomatic liver disease with serum albumin \< 3 G/DL~ * PT or PTT \> ULN, or~ * Chronic liver disease~* Documented forced vital capacity \< 50% of predicted

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo injection (Type: PLACEBO_COMPARATOR): patients receive normal saline injection twice weekly for weeks 1-12
- Etanercept (Type: EXPERIMENTAL): patients receive etanercept injection twice weekly for weeks 1-12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues